Feb. 23, 2010 /PRNewswire-FirstCall/ — Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma. A Phase II clinical trial of …
Trending at Lumira Ventures
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Learn More-External Link
Ception Therapeutics Initiates Phase II/III Clinical Trial…
Learn More-External Link
Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Fina…
Learn More-External Link
Ception Therapeutics Raises $63 Million in Series C Financing.
MALVERN, PA – January 29, 2007 – Ception Therapeutics, Inc., an emerging biopharmaceutical company discovering and developing novel biologic and small-molecule agents to address unmet medical needs, today announced that it has raised $63 million through a Series C private …